Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 81.1%

Neg 0% Neu 0% Pos 81.1%

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $40.